FDA clears Abbott CardioMEMS updates that let patients view heart pressure via a new app
Abbott Laboratories received FDA approval for enhancements to its CardioMEMS HF System. The updates add a patient‑facing CardioGuide HF mobile app that displays pulmonary artery pressure readings and a Dynamic Treatment Plan feature that can send personalized medication instructions. Abbott said the software will be rolled out to U.S. patients later in 2026.
Why it matters
The approval enables Abbott to offer a digital tool that may improve heart‑failure management by giving patients earlier insight into pressure changes, which could reduce hospitalizations. Abbott expects the app and treatment‑plan feature to be available later in 2026, expanding its CardioMEMS service offering.
Key facts
- 1The U.S. Food and Drug Administration approved updates to Abbott's CardioMEMS HF System that add patient‑facing capabilities. stocktitan.net
- 2The new CardioGuide HF App will let U.S. CardioMEMS patients view their pulmonary artery pressure readings on iOS or Android devices. uk.investing.com
- 3The Dynamic Treatment Plan feature allows clinicians to set personalized medication adjustment plans that are delivered to patients through the app. marketscreener.com
- 4Abbott intends to launch the CardioGuide HF App and Dynamic Treatment Plan later in 2026. stocktitan.net
- 5Abbott states the CardioMEMS system has been shown in clinical studies to reduce heart‑failure hospitalizations and mortality risk. uk.investing.com
Summary written by AlphAI from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.